Lyramid: Inflammatory and Fibrotic Diseases
holds has the most comprehensive global patent portfolio around the use of
anti-MK agents for treating inflammatory and other diseases. The company has a
pre-clinical program in place (CAB101) to evaluate novel anti-MK antibodies in
the treatment of conditions such as chronic kidney disease.
shown that MK is involved in pro-inflammatory processes and induces
inflammation via several mechanisms. Cellmid’s CAB101 anti-MK antibody is
designed to sequester circulating MK in the body, inhibiting its action and
preventing it from promoting and perpetuating unwanted inflammation and
associated fibrotic processes.
CAB101 anti-MK antibody therapy aims to fulfil a massive unmet medical need for
safe and effective anti-inflammatory and anti-fibrotic compounds. Therapeutic antibodies
have proven safety profiles and are
suitable for long term use making Cellmid’s CAB101 anti-MK antibody therapy a
feasible drug candidate in several disease indications.
An area of significant
unmet need in the community is in chronic kidney disease (CKD), with an
estimated 10-14% of adults in the developed world having some evidence of
CKD. In the US, prevalence of CKD in the adult population equates to ~20
million individuals. CKD is thought to be responsible for up to one million deaths
per annum worldwide. This level of disease in the
population creates an enormous financial burden particularly on the public
healthcare system. In the US, the
treatment of CKD and dialysis patients is responsible for 20% of Medicare
expenditure, which is representative of 3% of the total federal budget.
CKD incidence is associated with poor diet
and lifestyle and increases with age. As there is a large aging population
bubble in the western world accompanied by increasing obesity rates, the
incidence of CKD is predicted to rise.
The global market for therapeutics for Renal and Kidney disease is
predicted to reach US$73 billion by 2017.
that anti-MK therapy may be useful is in liver disease, in particular Non-Alcoholic
steatohepatitis (NASH). NASH has been described as ‘the next global epidemic’
(Defined Health 2015), and its incidence is associated with poor diet and
lifestyle. In the US 30% of adults (80 million
individuals) and 10% of children are thought to have liver disease, and 10-30%
of these have progressed to NASH, with 25-40% of NASH patients at risk of
developing advanced hepatic fibrosis.
Despite the large societal and healthcare burden that NASH represents,
there are no FDA approved drugs for the condition making this an area of
extreme unmet need. It has been
forecasted that the market for NASH treatments could reach US$35-40 billion by
2025 (Defined Health 2015).